XBB.1.5 monovalent booster improves antibody binding and neutralization against emerging SARS-CoV-2 Omicron variants
Shilpi Jain, Sanjeev Kumar, Lilin Lai, Susanne Linderman, Ansa A. Malik, Madison L. Ellis, Sucheta Godbole, Daniel Solis, Malaya K. Sahoo, Kareem Bechnak, Isabel Paredes, Ralph Tanios, Bahaa Kazzi, Serena M. Dib, Matthew B Litvack, , Mehul S. Suthar
The paper evaluates the effectiveness of an XBB.1.5 monovalent booster vaccine, showing improved antibody binding and neutralization against SARS-CoV-2 Omicron variants.
bioRxiv · Feb 3, 2024 · PreprintImmunology